Nevis Brands, Inc. is a biotechnology company, which engages in developing breakthrough treatments in the field of immuno-oncology. It focuses on the following technologies: PAS-403 for glioblastoma, PAS-393 for cancer, and Pre-BCR Antibody for leukemia. The company was founded by Wilfred Jefferies on January 28, 2011 and is headquartered in Vancouver, Canada.